IDEAYA Biosciences, Inc.(IDYA US)
$31.83+0.341.08%
Get the full experience
We save the real magic for signed-in users.
Get the full experience
We save the real magic for signed-in users.
| Millions USD (ex. Per Share) | FY201712/31/2017 | FY201812/31/2018 | FY201912/31/2019 | FY202012/31/2020 | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M03/31/2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | 157.0 | 84.4 | 112.8 | 157.5 | ||||||||
| Short Term Investments | 368.1 | 591.9 | 526.6 | 513.7 | ||||||||
| Cash and Short Term Investments | 525.1 | 676.3 | 639.4 | 671.2 | ||||||||
| Net Receivables | 0.0 | 0.0 | 6.0 | 6.6 | ||||||||
| Inventory | - | - | - | - | ||||||||
| Other Current Assets | 7.5 | 13.4 | 21.4 | 18.3 | ||||||||
| Total Current Assets | 532.6 | 689.7 | 666.7 | 696.1 | ||||||||
| Property, Plant & Equipment | 8.4 | 27.7 | 31.3 | 31.2 | ||||||||
| Long Term Investments | 107.5 | 405.8 | 410.3 | 301.7 | ||||||||
| Other Non-Current Assets | 0.8 | 0.8 | 1.0 | 1.3 | ||||||||
| Total Non-Current Assets | 116.7 | 434.4 | 442.6 | 334.2 | ||||||||
| Total Assets | 649.3 | 1,124.1 | 1,109.3 | 1,030.3 | ||||||||
| Account Payables | 6.6 | 15.4 | 17.6 | 20.7 | ||||||||
| Short Term Debt | - | - | 0.3 | 0.4 | ||||||||
| Deferred Revenue | - | - | - | - | ||||||||
| Other Current Liabilities | 11.8 | 30.4 | 29.7 | 37.5 | ||||||||
| Total Current Liabilities | 27.1 | 46.1 | 58.8 | 64.8 | ||||||||
| Long Term Debt | - | - | 27.6 | 28.3 | ||||||||
| Other Non-Current Liabilities | - | - | - | - | ||||||||
| Total Non-Current Liabilities | 1.1 | 18.9 | 27.6 | 28.3 | ||||||||
| Total Liabilities | 28.2 | 64.9 | 86.4 | 93.1 | ||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | ||||||||
| Retained Earnings | -348.4 | -622.8 | -736.5 | -835.1 | ||||||||
| Total Stockholders Equity | 621.1 | 1,059.1 | 1,022.9 | 937.3 | ||||||||
| Total Liabilities and Equity | 649.3 | 1,124.1 | 1,109.3 | 1,030.3 | ||||||||
| Millions USD (ex. Per Share) | FY201712/31/2017 | FY201812/31/2018 | FY201912/31/2019 | FY202012/31/2020 | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M03/31/2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | 157.0 | 84.4 | 112.8 | 157.5 | ||||||||
| Short Term Investments | 368.1 | 591.9 | 526.6 | 513.7 | ||||||||
| Cash and Short Term Investments | 525.1 | 676.3 | 639.4 | 671.2 | ||||||||
| Net Receivables | 0.0 | 0.0 | 6.0 | 6.6 | ||||||||
| Inventory | - | - | - | - | ||||||||
| Other Current Assets | 7.5 | 13.4 | 21.4 | 18.3 | ||||||||
| Total Current Assets | 532.6 | 689.7 | 666.7 | 696.1 | ||||||||
| Property, Plant & Equipment | 8.4 | 27.7 | 31.3 | 31.2 | ||||||||
| Long Term Investments | 107.5 | 405.8 | 410.3 | 301.7 | ||||||||
| Other Non-Current Assets | 0.8 | 0.8 | 1.0 | 1.3 | ||||||||
| Total Non-Current Assets | 116.7 | 434.4 | 442.6 | 334.2 | ||||||||
| Total Assets | 649.3 | 1,124.1 | 1,109.3 | 1,030.3 | ||||||||
| Account Payables | 6.6 | 15.4 | 17.6 | 20.7 | ||||||||
| Short Term Debt | - | - | 0.3 | 0.4 | ||||||||
| Deferred Revenue | - | - | - | - | ||||||||
| Other Current Liabilities | 11.8 | 30.4 | 29.7 | 37.5 | ||||||||
| Total Current Liabilities | 27.1 | 46.1 | 58.8 | 64.8 | ||||||||
| Long Term Debt | - | - | 27.6 | 28.3 | ||||||||
| Other Non-Current Liabilities | - | - | - | - | ||||||||
| Total Non-Current Liabilities | 1.1 | 18.9 | 27.6 | 28.3 | ||||||||
| Total Liabilities | 28.2 | 64.9 | 86.4 | 93.1 | ||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | ||||||||
| Retained Earnings | -348.4 | -622.8 | -736.5 | -835.1 | ||||||||
| Total Stockholders Equity | 621.1 | 1,059.1 | 1,022.9 | 937.3 | ||||||||
| Total Liabilities and Equity | 649.3 | 1,124.1 | 1,109.3 | 1,030.3 | ||||||||